

- phoma (PRIMEUR-IVL): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*, 21(4):593-602.
[https://doi.org/10.1016/S1470-2045\(20\)30059-0](https://doi.org/10.1016/S1470-2045(20)30059-0)
- Yan Z, Chao C, Danqing Z, et al., 2023. A prospective single-center phase 2 study of zanubrutinib plus R-CHOP in treat-naïve intravascular large B cell lymphoma. EHA 2023 Abstract P1185.
- Geer M, Roberts E, Shango M, et al., 2019. Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. *Br J Haematol*, 186(2):255-262.
<https://doi.org/10.1111/bjh.15923>
- Mahadevan D, Spier C, Della Croce K, et al., 2005. Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. *Mol Cancer Ther*, 4(12):1867-1879.
<https://doi.org/10.1158/1535-7163.MCT-05-0146>
- Schmitz R, Wright GW, Huang DW, et al., 2018. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. *N Engl J Med*, 378(15):1396-1407.
<https://doi.org/10.1056/NEJMoa1801445>
- Poletto S, Novo M, Paruzzo L, et al., 2022. Treatment strategies for patients with diffuse large B-cell lymphoma. *Cancer Treat Rev*, 110:102443.
<https://doi.org/10.1016/j.ctrv.2022.102443>

unedited